Gabriel Moreno-González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gabriel Moreno-González has a total of 385 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Mussetti
Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
4 shared publications Anna Sureda
Catalan Institute of Oncology - Bellvitge Biomedical Research Institute, L´Hospitalet de LL, Spain
4 shared publicationsDjamel Mokart
Institut Paoli-Calmette, réanimation polyvalente et département d'anesthésie et de réanimation, Marseille, France
4 shared publications- Rafael Mañez
Infectious Diseases and Transplantation Division, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Spain
4 shared publications Alberto Mussetti
Catalan Institute of Oncology - Bellvitge Biomedical Research Institute, L´Hospitalet de LL, Spain
3 shared publications- Anna Sureda
Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
3 shared publications
Latest Publications
- Open Access
- 26 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9434
Caspase-3 in Brain Death Donors Is Associated with Reduced Primary Graft Dysfunction After Heart Transplantation
Primary graft dysfunction (PGD) remains a major cause of early morbidity and mortality after a heart transplant (HTx). Understanding the donor-related mechanisms involved may help improve organ selection and post-HTx outcomes. This study aimed to explore the association between the donor serum biomarkers of cell death and inflammation and the incidence of PGD and rejection in HTx recipients. We conducted a retrospective, multicenter observational study of brain-dead (DBD) heart donors and corresponding recipients between 2013 and 2019. Donor blood samples were analyzed for inflammatory cytokines, cell death-related proteins, and mitochondrial (mtDNA) and genomic DNA (gDNA). A total of 39 donor–recipient pairs were included. Sixteen recipients developed severe PGD, and five experienced ≥2R cellular rejection. Donors whose recipients developed PGD had significantly lower serum Caspase-3 levels compared to those without PGD (391.6 [101.8–1003.3] vs. 65.3 [40.2–163.3] pg/mL; p = 0.04). A trend toward lower mtDNA/gDNA ratio was also observed in the same group (10.5 [5.4–24.6] vs. 6.5 [3.3–10.7]; p = 0.067). Lower Caspase-3 levels in donor serum were significantly associated with the development of severe PGD in recipients. This may suggest that the sublethal activation of apoptotic pathways in the donor could play a protective role, potentially conditioning the graft to tolerate ischemic injury.
- 26 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9434
Open AccessCaspase-3 in Brain Death Donors Is Associated with Reduced Primary Graft Dysfunction After Heart Transplantation
Primary graft dysfunction (PGD) remains a major cause of early morbidity and mortality after a heart transplant (HTx). Understanding the donor-related mechanisms involved may help improve organ selection and post-HTx outcomes. This study aimed to explore the association between the donor serum biomarkers of cell death and inflammation and the incidence of PGD and rejection in HTx recipients. We conducted a retrospective, multicenter observational study of brain-dead (DBD) heart donors and corresponding recipients between 2013 and 2019. Donor blood samples were analyzed for inflammatory cytokines, cell death-related proteins, and mitochondrial (mtDNA) and genomic DNA (gDNA). A total of 39 donor–recipient pairs were included. Sixteen recipients developed severe PGD, and five experienced ≥2R cellular rejection. Donors whose recipients developed PGD had significantly lower serum Caspase-3 levels compared to those without PGD (391.6 [101.8–1003.3] vs. 65.3 [40.2–163.3] pg/mL; p = 0.04). A trend toward lower mtDNA/gDNA ratio was also observed in the same group (10.5 [5.4–24.6] vs. 6.5 [3.3–10.7]; p = 0.067). Lower Caspase-3 levels in donor serum were significantly associated with the development of severe PGD in recipients. This may suggest that the sublethal activation of apoptotic pathways in the donor could play a protective role, potentially conditioning the graft to tolerate ischemic injury.
- Open Access
- 4 August 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 5782-5792
Loss of β‐cell identity in human islets treated with glibenclamide
Aims: Loss of β‐cell identity can contribute to the reduction of functional β‐cell mass in type 2 diabetes. Sulfonylureas show shorter durability of antihyperglycaemic action and higher rates of secondary failure compared to other antihyperglycaemic agents, suggesting that they could accelerate the decline of β‐cell functional mass in type 2 diabetes. We aimed to investigate the impact of chronic exposure to sulfonylureas on β‐cell identity. Materials and Methods: Islets from human multi‐organ donors were cultured for 4–7 days at 5.6 mM glucose with or without glibenclamide. β‐cell function (glucose stimulated insulin secretion, GSIS), apoptosis (TUNEL) and gene (RT‐qPCR) and protein expression (immunofluorescence, genetic β‐cell tracing and Western Blot) were determined. Results: Human islets exposed to glibenclamide showed increased insulin secretion at low glucose, reduced GSIS, increased apoptosis, endoplasmic reticulum (ER) stress, and loss of β‐cell identity indicated by reduced gene and protein expression of key β‐cell identity markers and insulin. There were no changes in the expression of disallowed or progenitor‐related genes. Genetic β‐cell tracing showed a similar percentage of insulin‐expressing cells in control and sulfonylurea‐treated islets. Addition of the chemical chaperone 4‐phenylbutyrate (PBA) to the culture medium prevented glibenclamide‐induced ER stress and the downregulation of key β‐cell transcription factors, indicating that ER stress mediates, at least partially, the negative effects of glibenclamide on β‐cell identity. Conclusions: Chronic exposure of human islets to glibenclamide induced the loss of β‐cell identity, which was mediated by ER stress, impaired β‐cell function, and increased β‐cell apoptosis. These negative effects of glibenclamide may contribute to the secondary failure of sulfonylureas and accelerate the decline of functional β‐cell mass in patients with type 2 diabetes.
- 4 August 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 5782-5792
Open AccessLoss of β‐cell identity in human islets treated with glibenclamide
Aims: Loss of β‐cell identity can contribute to the reduction of functional β‐cell mass in type 2 diabetes. Sulfonylureas show shorter durability of antihyperglycaemic action and higher rates of secondary failure compared to other antihyperglycaemic agents, suggesting that they could accelerate the decline of β‐cell functional mass in type 2 diabetes. We aimed to investigate the impact of chronic exposure to sulfonylureas on β‐cell identity. Materials and Methods: Islets from human multi‐organ donors were cultured for 4–7 days at 5.6 mM glucose with or without glibenclamide. β‐cell function (glucose stimulated insulin secretion, GSIS), apoptosis (TUNEL) and gene (RT‐qPCR) and protein expression (immunofluorescence, genetic β‐cell tracing and Western Blot) were determined. Results: Human islets exposed to glibenclamide showed increased insulin secretion at low glucose, reduced GSIS, increased apoptosis, endoplasmic reticulum (ER) stress, and loss of β‐cell identity indicated by reduced gene and protein expression of key β‐cell identity markers and insulin. There were no changes in the expression of disallowed or progenitor‐related genes. Genetic β‐cell tracing showed a similar percentage of insulin‐expressing cells in control and sulfonylurea‐treated islets. Addition of the chemical chaperone 4‐phenylbutyrate (PBA) to the culture medium prevented glibenclamide‐induced ER stress and the downregulation of key β‐cell transcription factors, indicating that ER stress mediates, at least partially, the negative effects of glibenclamide on β‐cell identity. Conclusions: Chronic exposure of human islets to glibenclamide induced the loss of β‐cell identity, which was mediated by ER stress, impaired β‐cell function, and increased β‐cell apoptosis. These negative effects of glibenclamide may contribute to the secondary failure of sulfonylureas and accelerate the decline of functional β‐cell mass in patients with type 2 diabetes.
- Top Cited PapersOpen Access
- 22 February 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (7) , 1526-1539
DCDD heart transplantation with thoraco-abdominal normothermic regional perfusion and static cold storage: The experience in Spain
- 22 February 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (7) , 1526-1539
Top Cited PapersOpen AccessDCDD heart transplantation with thoraco-abdominal normothermic regional perfusion and static cold storage: The experience in Spain
- Open Access
- 1 November 2023
- Published by Frontiers Media SA in Frontiers in Transplantation
- Vol. 2, 1280454
Outcomes of liver transplantation with thoracoabdominal normothermic regional perfusion: a matched-controlled initial experience in Spain
Thoracoabdominal (TA) normothermic regional perfusion (NRP) should allow the safe recovery of heart and liver grafts simultaneously in the context of controlled donation after circulatory death (cDCD). We present the initial results of cDCD liver transplantation with simultaneous liver and heart procurement in Spain until October 2021. Outcomes were compared with a matched cohort of cDCD with abdominal NRP (A-NRP) from participating institutions. Primary endpoints comprised early allograft dysfunction (EAD) or primary non-function (PNF), and the development of ischemic-type biliary lesions (ITBL). Six transplants were performed using cDCD with TA-NRP during the study period. Donors were significantly younger in the TA-NRP group than in the A-NRP group (median 45.6 years and 62.9 years respectively, p = 0.011), with a median functional warm ischemia time of 12.5 min in the study group and 13 min in the control group. Patient characteristics, procurement times, and surgical baseline characteristics did not differ significantly between groups. No patient in the study group developed EAD or PNF, and over a median follow-up of 9.8 months, none developed ITBL or graft loss. Extending A-NRP to TA-NRP for cardiac procurement may be technically challenging, but it is both feasible and safe, showing comparable postoperative outcomes to A-NRP.
- 1 November 2023
- Published by Frontiers Media SA in Frontiers in Transplantation
- Vol. 2, 1280454
Open AccessOutcomes of liver transplantation with thoracoabdominal normothermic regional perfusion: a matched-controlled initial experience in Spain
Thoracoabdominal (TA) normothermic regional perfusion (NRP) should allow the safe recovery of heart and liver grafts simultaneously in the context of controlled donation after circulatory death (cDCD). We present the initial results of cDCD liver transplantation with simultaneous liver and heart procurement in Spain until October 2021. Outcomes were compared with a matched cohort of cDCD with abdominal NRP (A-NRP) from participating institutions. Primary endpoints comprised early allograft dysfunction (EAD) or primary non-function (PNF), and the development of ischemic-type biliary lesions (ITBL). Six transplants were performed using cDCD with TA-NRP during the study period. Donors were significantly younger in the TA-NRP group than in the A-NRP group (median 45.6 years and 62.9 years respectively, p = 0.011), with a median functional warm ischemia time of 12.5 min in the study group and 13 min in the control group. Patient characteristics, procurement times, and surgical baseline characteristics did not differ significantly between groups. No patient in the study group developed EAD or PNF, and over a median follow-up of 9.8 months, none developed ITBL or graft loss. Extending A-NRP to TA-NRP for cardiac procurement may be technically challenging, but it is both feasible and safe, showing comparable postoperative outcomes to A-NRP.
- Open Access
- 6 March 2023
- Published by Springer Nature in Research Square
Phase I Clinical Trial. Safety of Baricitinib to prevent respiratory insufficiency in oncohematological patients affected by Coronavirus Disease-19: BARCOVID19 study
Background Oncohematological patients, due to their secondary immunodeficiency, are at a higher risk of mortality related to COVID-19 infection. Baricitinib, a JAK2 inhibitor, has a dual effect in this context, reducing the inflammatory response to the virus and diminishing virus endocytosis. Methods This phase I safety run-in cohort study aimed to determine the dose-limiting toxicity of baricitinib in terms of the rate of serious events in oncohematological patients with COVID-19. The drug was administered on an inpatient basis at an oral dose of 4 mg daily for 5 to 7 days, associated with the institutional standard of care (SOC). Results Six patients with solid tumors or hematological malignancies were enrolled in the study. Sixty percent of the patients received active anticancer treatment at the time of inclusion. Lymphopenia and elevation of acute-phase reactants were the most frequent laboratory findings that improved during the treatment course. All patients received corticosteroids, but only 3 of them received remdesivir as the SOC. The most common adverse events were bacterial infections, including pneumonia, urinary tract infections, and bacteremia. The mortality rate due to disease progression and respiratory insufficiency is 33%. The severe adverse event rate was less than 33%, with no adverse events or mortality caused by baricitinib. Conclusions The results of the present study demonstrate that baricitinib is a safe treatment for patients with oncohematological diseases and COVID-19. However, its efficacy and superiority to standard treatment will require further testing in phases 2 and 3 trials. Trial registration: AEMPs: 20–0356 EudraCT: 2020-001789-12
- 6 March 2023
- Published by Springer Nature in Research Square
Open AccessPhase I Clinical Trial. Safety of Baricitinib to prevent respiratory insufficiency in oncohematological patients affected by Coronavirus Disease-19: BARCOVID19 study
Background Oncohematological patients, due to their secondary immunodeficiency, are at a higher risk of mortality related to COVID-19 infection. Baricitinib, a JAK2 inhibitor, has a dual effect in this context, reducing the inflammatory response to the virus and diminishing virus endocytosis. Methods This phase I safety run-in cohort study aimed to determine the dose-limiting toxicity of baricitinib in terms of the rate of serious events in oncohematological patients with COVID-19. The drug was administered on an inpatient basis at an oral dose of 4 mg daily for 5 to 7 days, associated with the institutional standard of care (SOC). Results Six patients with solid tumors or hematological malignancies were enrolled in the study. Sixty percent of the patients received active anticancer treatment at the time of inclusion. Lymphopenia and elevation of acute-phase reactants were the most frequent laboratory findings that improved during the treatment course. All patients received corticosteroids, but only 3 of them received remdesivir as the SOC. The most common adverse events were bacterial infections, including pneumonia, urinary tract infections, and bacteremia. The mortality rate due to disease progression and respiratory insufficiency is 33%. The severe adverse event rate was less than 33%, with no adverse events or mortality caused by baricitinib. Conclusions The results of the present study demonstrate that baricitinib is a safe treatment for patients with oncohematological diseases and COVID-19. However, its efficacy and superiority to standard treatment will require further testing in phases 2 and 3 trials. Trial registration: AEMPs: 20–0356 EudraCT: 2020-001789-12
- 1 March 2023
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 76 (7) , 568-571
Potential for controlled heart donation after circulatory determination of death
- 1 March 2023
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 76 (7) , 568-571
Potential for controlled heart donation after circulatory determination of death
- 27 January 2023
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 76 (7) , 568-571
Potencialidad de la donación cardiaca de donantes en asistolia controlada
- 27 January 2023
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 76 (7) , 568-571
Potencialidad de la donación cardiaca de donantes en asistolia controlada
- 19 January 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (1) , e14008
Transplantation of organs from SARS‐CoV‐2‐positive donors: Preliminary experience from Spain
Background: The utilization of non‐lung organs from deceased donors with a positive polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) at the time of donation can be lifesaving, although the safety of this policy must be assessed.Methods: This is a nationwide, prospective study, reporting the experience on the utilization of non‐lung organs from SARS‐CoV‐2‐positive donors between December 15, 2020 and May 31, 2022 in Spain.Results: A total of 69 patients received a solid organ transplant (41 kidney, 18 liver, 8 heart, and 2 combined liver–kidney) obtained from 32 donors with a positive SARS‐CoV‐2 PCR at the time of donation (four of them with a cycle threshold value <30). All recipients tested negative for SARS‐CoV‐2 and were free of coronavirus disease 2019 (COVID‐19) symptoms prior to transplantation. Nasopharyngeal swab turned positive for SARS‐CoV‐2 PCR in 4 (5.8%) recipients at 3, 8, 11, and 20 days after transplantation, though evidence did not support a donor‐derived COVID‐19. Four kidney recipients lost their grafts and two patients died: one heart recipient due to cardiogenic shock and one combined liver–kidney recipient due to lung hypertension and right heart failure. Graft losses and patient deaths were deemed unrelated to the donor SARS‐CoV‐2 status by the treating teams. No other adverse reactions were reported.Conclusions: This preliminary experience supports the safety of the use of organs other than lungs from SARS‐CoV‐2 PCR‐positive donors, in alignment with previous series. However, the impact of SARS‐CoV‐2 infection upon organ quality should be established in future research. image
- 19 January 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (1) , e14008
Transplantation of organs from SARS‐CoV‐2‐positive donors: Preliminary experience from Spain
Background: The utilization of non‐lung organs from deceased donors with a positive polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) at the time of donation can be lifesaving, although the safety of this policy must be assessed.Methods: This is a nationwide, prospective study, reporting the experience on the utilization of non‐lung organs from SARS‐CoV‐2‐positive donors between December 15, 2020 and May 31, 2022 in Spain.Results: A total of 69 patients received a solid organ transplant (41 kidney, 18 liver, 8 heart, and 2 combined liver–kidney) obtained from 32 donors with a positive SARS‐CoV‐2 PCR at the time of donation (four of them with a cycle threshold value <30). All recipients tested negative for SARS‐CoV‐2 and were free of coronavirus disease 2019 (COVID‐19) symptoms prior to transplantation. Nasopharyngeal swab turned positive for SARS‐CoV‐2 PCR in 4 (5.8%) recipients at 3, 8, 11, and 20 days after transplantation, though evidence did not support a donor‐derived COVID‐19. Four kidney recipients lost their grafts and two patients died: one heart recipient due to cardiogenic shock and one combined liver–kidney recipient due to lung hypertension and right heart failure. Graft losses and patient deaths were deemed unrelated to the donor SARS‐CoV‐2 status by the treating teams. No other adverse reactions were reported.Conclusions: This preliminary experience supports the safety of the use of organs other than lungs from SARS‐CoV‐2 PCR‐positive donors, in alignment with previous series. However, the impact of SARS‐CoV‐2 infection upon organ quality should be established in future research. image
- 16 June 2022
- Published by Elsevier in Bulletin du Cancer
- Vol. 109 (9) , 916-924
When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study
- 16 June 2022
- Published by Elsevier in Bulletin du Cancer
- Vol. 109 (9) , 916-924
When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study
- Top Cited PapersOpen Access
- 17 February 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (2) , 283-294
The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration
Bioprosthetic heart valves (BHVs) are commonly used to replace severely diseased heart valves but their susceptibility to structural valve degeneration (SVD) limits their use in young patients. We hypothesized that antibodies against immunogenic glycans present on BHVs, particularly antibodies against the xenoantigens galactose-α1,3-galactose (αGal) andN-glycolylneuraminic acid (Neu5Gc), could mediate their deterioration through calcification. We established a large longitudinal prospective international cohort of patients (n = 1668, 34 ± 43 months of follow-up (0.1–182); 4,998 blood samples) to investigate the hemodynamics and immune responses associated with BHVs up to 15 years after aortic valve replacement. Early signs of SVD appeared in <5% of BHV recipients within 2 years. The levels of both anti-αGal and anti-Neu5Gc IgGs significantly increased one month after BHV implantation. The levels of these IgGs declined thereafter but anti-αGal IgG levels declined significantly faster in control patients compared to BHV recipients. Neu5Gc, anti-Neu5Gc IgG and complement deposition were found in calcified BHVs at much higher levels than in calcified native aortic valves. Moreover, in mice, anti-Neu5Gc antibodies were unable to promote calcium deposition on subcutaneously implanted BHV tissue engineered to lack αGal and Neu5Gc antigens. These results indicate that BHVs manufactured using donor tissues deficient in αGal and Neu5Gc could be less prone to immune-mediated deterioration and have improved durability.
- 17 February 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (2) , 283-294
Top Cited PapersOpen AccessThe role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration
Bioprosthetic heart valves (BHVs) are commonly used to replace severely diseased heart valves but their susceptibility to structural valve degeneration (SVD) limits their use in young patients. We hypothesized that antibodies against immunogenic glycans present on BHVs, particularly antibodies against the xenoantigens galactose-α1,3-galactose (αGal) andN-glycolylneuraminic acid (Neu5Gc), could mediate their deterioration through calcification. We established a large longitudinal prospective international cohort of patients (n = 1668, 34 ± 43 months of follow-up (0.1–182); 4,998 blood samples) to investigate the hemodynamics and immune responses associated with BHVs up to 15 years after aortic valve replacement. Early signs of SVD appeared in <5% of BHV recipients within 2 years. The levels of both anti-αGal and anti-Neu5Gc IgGs significantly increased one month after BHV implantation. The levels of these IgGs declined thereafter but anti-αGal IgG levels declined significantly faster in control patients compared to BHV recipients. Neu5Gc, anti-Neu5Gc IgG and complement deposition were found in calcified BHVs at much higher levels than in calcified native aortic valves. Moreover, in mice, anti-Neu5Gc antibodies were unable to promote calcium deposition on subcutaneously implanted BHV tissue engineered to lack αGal and Neu5Gc antigens. These results indicate that BHVs manufactured using donor tissues deficient in αGal and Neu5Gc could be less prone to immune-mediated deterioration and have improved durability.